Clinicolaboratory characteristics of patients with primary biliary cirrhosis associated with CREST symptoms

• Published in: Hepatology research Vol. 22; no. 3; p. 187
• Main Authors: Tojo, Jun, Ohira, Hiromasa, Suzuki, Tomohiro, Takeda, Isao, Shoji, Isao, Kojima, Toshihiko, Takagi, Toru, Kuroda, Masahito, Miyata, Masayuki, Nishimaki, Tomoe, Ohnami, Kozo, Kanno, Takashi, Mukai, Shinji, Kasukawa, Reiji
• Format: Journal Article
• Language: English
• Published: Netherlands 01.03.2002
• ISSN: 1386-6346
• DOI: 10.1016/S1386-6346(01)00138-3

Aims: Patients with primary biliary cirrhosis (PBC) occasionally suffer complications from other autoimmune diseases. When PBC was associated with calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly and telangiectasias (CREST) symptoms, it has been proposed that it is a distinct clinical entity. This study aimed to investigate whether PBC associated with CREST symptoms is a distinct disease complex. Method: Clinicolaboratory data, HLA type of leukocytes and disease prognosis were compared between 31 patients with PBC associated with CREST symptoms and 68 patients with PBC alone. Results: The characteristic findings and significant differences observed in patients with PBC associated with CREST symptoms compared with PBC alone are as follows: all women with older age with milder clinical features of both PBC (asymptomatic PBC in 84%) and CREST syndrome (incomplete CREST in 81%), more frequent occurrence of esophageal varices (28.6 vs. 9.3%), better prognosis (87.5 vs. 45.5% in 10 years survival), lower serum levels of AST (39.8 vs. 63.6 IU/l) and IgM (460 vs. 676 mg/dl), higher prevalence of discrete speckled pattern of antinuclear antibodies (93.5 vs. 12.3%), higher median titers of anti-CENP-B antibodies (1.22 vs. 0.31), lower median titers of antimitochondrial antibody (1:80 vs. 1:160), and a higher prevalence of HLA-DR9 (54.5 vs. 24.3%). Conclusion: These findings support the presence of a subgroup in PBC as PBC associated with CREST symptoms.